Evidence map›Paper›PMID 40172786›Full record

ArticleBreast cancer (Tokyo, Japan)2025

Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer.

Mao Uematsu, Hiromichi Nakajima, Hirohiko Miyake, Masashi Wakabayashi, Chikako Funasaka, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Ako Hosono, Yoichi Naito and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mao UematsuDepartment of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.ORCID http://orcid.org/0009-0003-6566-5943
Hiromichi NakajimaDepartment of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan. hiromina@east.ncc.go.jp.ORCID http://orcid.org/0000-0001-6401-4258
Hirohiko MiyakeDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
Masashi WakabayashiBiostatistics Division, Center for Research Administration and Support, National Cancer Center, Chuo-Ku, Japan.
Chikako FunasakaDepartment of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
Chihiro KondohDepartment of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
Kenichi HaranoDepartment of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
Nobuaki MatsubaraDepartment of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
Ako HosonoDepartment of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
Yoichi NaitoDepartment of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
Naoya SakamotoDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
Motohiro KojimaDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
Tatsuya OnishiDepartment of Breast Surgery, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
Genichiro IshiiCourse of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Bunkyō, Japan.ORCID http://orcid.org/0000-0001-8637-3323
Toru MukoharaDepartment of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.ORCID http://orcid.org/0000-0002-8573-418X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe area of residual tumor (ART) is a quantitative method for assessing tumors after neoadjuvant chemotherapy (NAC). This study evaluated whether ART can identify a favorable prognosis group in patients with HER2-positive surgically resected breast cancer and residual tumors post-NAC.

methodsWe retrospectively reviewed patients with HER2-positive who underwent surgery after NAC, including trastuzumab, from 2005 to 2022 at our institution. ART was assessed at the maximum cut surface of the residual primary tumor using digital pathology images. Receiver operating characteristic curve analysis determined ART-Low and ART-High cutoffs, excluding ART-0 (0 mm

resultsOf the 219 patients, 82 had ART greater than 0 mm

conclusionsThe current study suggests that even minimal residual tumor cells in the primary site can significantly impact on prognosis in HER2-positive early breast cancer.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsNeoplasm, ResidualAdultAgedChemotherapy, AdjuvantErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansMiddle AgedNeoadjuvant TherapyPrognosisRetrospective StudiesTrastuzumabERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabArea of residual tumorBiomarkerDigital pathologyHER2-positive breast cancerNeoadjuvant chemotherapy

Identifiers

PMID40172786
PMCPMC12174267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.